Skip to main content

Posters

October 09, 2020
Introduction: Depressive episodes/symptoms of bipolar I disorder (BPD-I) are commonly misdiagnosed as major depressive disorder (MDD). We developed the novel and pragmatic Rapid Mood Screener (RMS) to screen for manic symptoms and BPD-I risk factors (eg, age of onset) to improve misdiagnosis of BPD…
October 09, 2020
Among patients with schizophrenia (SZ) and bipolar I disorder (BD-I) treated with second-generation antipsychotics (SGAs), clinically-significant weight gain (CSWG) and treatment interruptions (TIs) are challenges that may result in morbidity/mortality.  
October 09, 2020
Objective: To compare the risk of hospitalization for adults with bipolar I disorder (BPD-I) when treated with lurasidone vs. other atypical antipsychotics (AAPs) as monotherapy.
October 09, 2020
Background: The aim of this analysis was to evaluate the long-term efficacy of lurasidone in achieving response and remission in children and adolescents with bipolar depression.
October 09, 2020
Background: Bipolar disorder (BPD) is a chronic, episodic illness affecting nearly 50 million globally, with disability mostly due to depressive episodes (MDEs). Zuranolone is an investigational oral neuroactive steroid GABAA receptor positive allosteric modulator. This open-label Phase 2 trial (…
October 09, 2020
Objectives: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable formulation of aripiprazole licensed in the US, Canada and Australia for maintenance treatment of adults with BP-I. Here we evaluate the effect of long-term AOM 400 maintenance treatment on functioning in BP-I…
October 09, 2020
Objective: 1. to discern demographic predictors that may extend hospitalization length of stay (LOS) for bipolar disorder (BP) managed with electroconvulsive therapy (ECT), and 2. to study the impact of insurance and hospital characteristics on LOS.
October 09, 2020
Depression is often the initial and predominant disease presentation in patients with bipolar disorder leading to their frequent misdiagnosis with major depressive disorder. Primary care clinicians (PCCs) are often the first and only healthcare providers for patients with mental health issues, so…
October 09, 2020
Background: The aim of these analyses was to assess the effect of lurasidone on manic symptoms and treatment-emergent (TE) mania in pediatric patients with bipolar depression.
October 09, 2020
Background: Treatments for bipolar depression are limited. Lumateperone (lumateperone tosylate, ITI-007), a mechanistically novel antipsychotic that simultaneously modulates serotonin, dopamine, and glutamate neurotransmission, is FDA-approved for the treatment of schizophrenia. This phase 3…
Back to Top